Press Release / Mar 19, 2018
Hovione reports on recent capacity expansion and future plans to support growth
Hovione reported today recent capacity expansion and future plans in its sites in Portugal, Ireland and New Jersey.
The authors discuss the preparedness of European regulatory authorities to implement and enforce the recent EU Directives 2004/27 and 2004/28, which require that all medicines marketed in the EU be made with active pharmaceutical ingredients (APIs) that comply with the harmonized GMP standard ICH/Q7A.